Catalyst

Slingshot members are tracking this event:

Janssen's(JNJ) XARELTO (rivaroxaban) 10 mg Dose in Reducing the Risk of Recurrent Venous Thromboembolism (VTE) PDUFA expected October 28, 2017

Source Link:
https://www.jnj.com/media-center/press-releases/us-fda-grants-priority-review-of-xarelto-rivaroxaban-snda-for-a-10-mg-dose-to-reduce-the-risk-of-recurrent-venous-thromboembolism-vte

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
JNJ Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 30, 2017
Occurred Source:
https://www.drugs.com/newdrugs/fda-approves-new-10-mg-dosing-xarelto-rivaroxaban-reduce-continued-risk-venous-thromboembolism-vte-4623.html
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Xarelto, Rivaroxaban, Venous Thromboembolism
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.